Genetically engineered biological therapy of severe bronchial asthma with benralizumab

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Genetically engineered biological therapy (GEBT) of bronchial asthma (BA) is a modern method of treating severe forms of the disease that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, six monoclonal antibody drugs for the treatment of severe bronchial asthma (anti-IgE – omalizumab), interleukin (IL)-5 antagonists (anti-IL-5 – mepolizumab, reslizumab) and its receptor (anti-IL-5Rα – benralizumab), as well as antibodies that selectively bind to the IL-4 and IL-13 receptor (anti-IL-4/13Rα - dupilumab) and tezepelumab, promoting the inhibition of thymic stromal lymphopoietin (TSLP) are registered in Russia.

A special group consists of patients with the eosinophilic phenotype of BA, characterized by a severe uncontrolled course and resistance to standard treatment regimens in accordance with the basic step therapy of the disease.

The article presents a clinical case of the effectiveness of GEBT using benralizumab as an example in a patient with severe uncontrolled bronchial asthma (eosinophilic phenotype).

全文:

受限制的访问

作者简介

Elena Trushina

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education; Tambov State University named after G.R. Derzhavin

编辑信件的主要联系方式.
Email: trushina.lena@mail.ru
ORCID iD: 0000-0001-5673-9195
SPIN 代码: 2164-6580

Cand. Sci. (Med.), Associate Professor, Department of Pulmonology and Phthisiology, Associate Professor, Department of Hospital Therapy with a Course in Psychiatry, Institute of Medicine and Health Protection

俄罗斯联邦, Penza; Tambov

Elena Kostina

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
ORCID iD: 0000-0003-1797-8040
俄罗斯联邦, Penza

Valery Tipikin

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
ORCID iD: 0009-0000-0990-4661
俄罗斯联邦, Penza

Ilya Illarionov

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
ORCID iD: 0009-0008-0725-3242
俄罗斯联邦, Penza

Ekaterina Orlova

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
俄罗斯联邦, Penza

Alina Turovskaya

Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: trushina.lena@mail.ru
ORCID iD: 0000-0002-5138-808X
俄罗斯联邦, Penza

参考

  1. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. 2024 URL: https://ginasthma.org/wp-content/uploads/2024/11/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf
  2. Клинические рекомендации. Бронхиальная астма. 2024. [Clinical guidelines. Bronchial asthma. 2024. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/view-cr/359_3 (дата обращения / date of access: 20.03.2025).
  3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2023. URL: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf
  4. Holguin F., Cardet J.C., Chung K.F. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55,1900588. https://dx.doi.org/10.1183/13993003.00588-2019
  5. Huang K., Yang T., Xu J., et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet 2019;394:407–418. https://dx.doi.org/10.1016/s0140-6736(19)31147-x
  6. Княжеская Н.П., Анаев Э.Х., Камелева А.А. и др. Таргетная терапия бронхиальной астмы. Бенрализумаб: в фокусе внимания пациенты, принимающие системные глюкокортикостероиды. Медицинский совет. 2020;17:9–16. [Knyazheskaya N.P., Anaev E.Kh., Kameleva A.A. et al. Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids. Meditsinskiy sovet=Medical Council. 2020;(17):9–16. (In Russ.)]. https://doi.org/10.21518/2079-701X-2020-17-9-16
  7. Bourdin А., Brusselle G., Couillard S., et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. J Allergy Clin Immunol Pract. 2024;12:809–823. https://dx.doi.org/10.1016/j.jaip.2024.01.023
  8. Chung K.F., Adcock I.M. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74:1649–1659. https://dx.doi.org/10.1111/all.13771
  9. Pavlidis S., Takahashi K., Ng Kee Kwong F., et al. T2-high in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J. 2019;53:1800938. https://dx.doi.org/10.1183/13993003.00938-2018
  10. Agache I., Beltran J., Akdis C., et al. Efficacy and safety of treatment with biologicals(benralizumab, dupilumab, mepolizumab, omalizumab andreslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on theuse of biologicals in severe asthma. Allergy. 2020;75:1023–1042. https://dx.doi.org/10.1111/all.14221
  11. Ненашева Н.М., Курбачева О.М., Авдеев С.Н. и др. Практические рекомендации по выбору иммунобиологического препарата для лечения тяжелой бронхиальной астмы Т2-эндотипа. Пульмонология. 2020;30(2):227–244. [Nenasheva N.M., Kurbacheva O.M., Avdeev S.N., et al. Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype. Russian Pulmonology. 2020;30(2):227?244. (In Russ.)]. https://dx.doi.org/10.18093/0869-0189-2020-30-2-227-244
  12. Edris A., De Feyter S., Maes T., et al. Monoclonal antibodies in type 2 asthma: a systematic review and network metaanalysis. Respir. Res. 2019;20(1):179. https://dx.doi.org/10.1186/s12931-019-1138-3
  13. Государственный реестр лекарственных средств. ЛП-000082. Ксолар (омализумаб). URL: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=d09dce42-ed01-4ff7-9c75-37757e0ff595
  14. Государственный реестр лекарственных средств. ЛП-004265. Синкейро (реслизумаб). [State Register of Medicines. LP-004265. Sinqueiro (reslizumab). (In Russ.)]. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=реслизумаб&token=c25e49f9-7c5d-46c6-9d9b-4133c36b37db
  15. Государственный реестр лекарственных средств. ЛП-004794. Нукала (меполизумаб). [State Register of Medicines. LP-004794. Nucala (mepolizumab). (In Russ.)]. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=меполизумаб&token=05e6b37f-7459-48b0-a331-0b3046264eee
  16. Государственный реестр лекарственных средств. ЛП-005492. Фазенра (бенрализумаб). [State Register of Medicines. LP-005492. Fasenra (benralizumab). (In Russ.)]. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=бенрализумаб&token=d61cfb09-8d15-4959-835c-ddf3dcc34fcf
  17. Государственный реестр лекарственных средств. ЛП-005440. Дупиксент (дупилумаб). [State Register of Medicines. LP-005440. Dupixent (dupilumab). URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=дупилумаб&token=b77c8e34-d0ca-48d8-b997-bab7b4d38315
  18. Государственный реестр лекарственных средств. ЛП-005440. Тезспире (тезепелумаб). [State Register of Medicines. LP-005440. Tesspire (tezepelumab). (In Russ.)]. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1&MnnR=тезепелумаб&token=ae5db859-7e6a-468a-891f-b1164c70aa61
  19. Agache I., Beltran J., Akdis C., et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023–1042. https://dx.doi.org/10.1111/all.14221
  20. Малявин А.Г., Козулина И.Е., Шарапова Ю.А. Пять молекул для таргетной биологической терапии тяжелой бронхиальной астмы: реалии и перспективы. Терапия. 2020;5:195–205. [Malyavin A.G., Kozulina I.E., Sharapova Yu.A. Five molecules for targeted biological therapy of severe bronchial asthma: realities and perspectives. Therapy. 2020;5:195–205. (In Russ.)]. https://dx.doi.org/10.18565/therapy.2020.5.195–205
  21. Menzies-Gow A., Wechsler M.E., Brightling C.E. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21:268. https://dx.doi.org/10.1186/s12931-020-01505-x
  22. Передельская М.Ю., Ненашева Н.М. Перспективы в лечении тяжелой бронхиальной астмы – обзор новой молекулы тезепелумаб. Практическая аллергология. 2023;2:56–61. [Peredelskaya M.Yu., Nenasheva N.M. Perspectives in the treatment of severe bronchial asthma - review of the new tezepelumab molecule. Practical Allergology. 2023;2:56–61(In Russ.)]. https://dx.doi.org/10.46393/27129667_2023_2_56
  23. Lambrecht B.N., Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. https://dx.doi.org/10.1038/ni.3049
  24. Титова О.Н., Кузубова Н.А., Склярова Д.Б., и др. Эффективность бенрализумаба при лечении эозинофильного фенотипа тяжелой бронхиальной астмы в условиях реальной клинической практики. Пульмонология. 2021;31(5):628–634. [Titova O.N., Kuzubova N.A., Sklyarova D.B., et al. The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice. Pul’monologiya. 2021;31(5):628–634. (In Russ.)]. https://dx.doi.org/10.18093/0869-0189-2021-31-5-628-634

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure. Clinical and inflammatory phenotypes of asthma. Adapted from [7]

下载 (582KB)
索引源数据

版权所有 © Bionika Media, 2025